Skip to main content
Clinical Trials/JPRN-UMIN000027050
JPRN-UMIN000027050
Completed
未知

The analysis about the efficacy of Rituximab against IgM anti-myelin-associated glycoprotein antibody demtelinating neuropathy - The analysis about the efficacy of Rituximab against IgM anti-myelin-associated glycoprotein antibody demtelinating neuropathy

Hyogo College of Medicine0 sites5 target enrollmentJuly 1, 2022

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Hyogo College of Medicine
Enrollment
5
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 1, 2022
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. Had received the treatment, including IVIg, plasma exchange, or steroid within past three months 2\. Has past history of hematological malignancy such as multiple myeloma, Waldenstroms macroglobulinemia, amyloidosis, and lymphoma 3\. Had received some sort of immunosuppressive therapy within past six months

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
The Evaluation of Efficacy and Safety of Rituximab (Genetical Recombination) in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients with Immunoglobulin G4 (IgG4) Autoantibodies in the Exploratory Clinical TrialChronic Inflammatory Demyelinating Polyneuropathy
JPRN-UMIN000035753agoya University Hospital27
Completed
Phase 2
RECIPE Trial
JPRN-jRCT2041180037Iijima Masahiro25
Completed
Phase 2
Rituximab in treatment of Rheumatoid arthritis in Indian patientsHealth Condition 1: null- Rheumatoid arthritisHealth Condition 2: M057- Rheumatoid arthritis with rheumatoid factor without organ or systems involvement
CTRI/2017/08/009321CENTER FOR RHEUMATIC DISEASES60
Active, not recruiting
Not Applicable
EVALUATION OF CLINICAL RESPONSE TO RITUXIMAB TREATMENT IN PATIENTS WITH ACQUIRED AUTOIMMUNE RECURRENT THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) - RITUXIMAB IN RECURRENT TTPTHROMBOTIC THROMBOCYTOPENIC PURPURAMedDRA version: 9.1Level: LLTClassification code 10037562
EUCTR2010-018794-38-ITFONDAZIONE IRCCS CA` GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO
Active, not recruiting
Not Applicable
Evaluación de la Eficacia de Rituximab en pacientes con Artritis Reumatoide a través de la medición, por Resonancia Magnética de Mano, de los parámetros clínicos de la enfermedad. Estudio RESONAR.Efficacy of rituximab in patients with Rheumatoid Arthritis, by measurement of disease parameters through magnetic resonance of the hand. RESONAR study.Pacientes con artritis reumatoide (AR) activa refractarios a uno o más fármacos antiTNF (definido por un DAS28>3,2).MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
EUCTR2008-002381-55-ESROCHE FARMA, S.A.